Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, leading to activation of the Wnt/β-catenin pathway and potential for aberrant cell proliferation. Development of GSK3α or GSK3β paralog-selective inhibitors that could offer an improved safety profile has been reported but further advancement has been hampered by the lack of structural information for GSK3α. Here we report for the first time the crystal structure for GSK3α, both in apo form and bound to a paralog-selective inhibitor. Taking advantage of this new structural information, we describe the design and in vitro testing of novel compounds with up to ∼37-fold selectivity for GSK3α over GSK3β with favorable drug-like properties. Furthermore, using chemoproteomics, we confirm that acute inhibition of GSK3α can lower tau phosphorylation at disease-relevant sites in vivo, with a high degree of selectivity over GSK3β and other kinases. Altogether, our studies advance prior efforts to develop GSK3 inhibitors by describing GSK3α structure and novel GSK3α inhibitors with improved selectivity, potency, and activity in disease-relevant systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GSK-3α ATP-competitive inhibitor 35 could cross the BBB and significantly reduce tau phosphorylation at pThr231 in neonatal rat brains”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As the role of GSK-3α in promoting Aβ production and tau phosphorylation in AD models is recognized”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
The cited source says what the claim attributes to it.
In the citing paper
“selective inhibition of GSK-3α has emerged as a promising therapeutic strategy.494,496,497”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Functional Interaction of an Axin Homolog, Conductin, with β-Catenin, APC, and GSK3β
Behrens, J., Jerchow, B.-A., Würtele, M., Grimm, J., Asbrand, C., Wirtz, R., Kühl, M., Wedlich, D., & Birchmeier, W. (1998) · Science · doi:10.1126/science.280.5363.596 · Cited by 1,260
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
Crystal Structure of Glycogen Synthase Kinase 3β
Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., & Pearl, L. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00374-9 · Cited by 674
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Miyoshi, Y., Iwao, K., Nagasawa, Y., Aihara, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., & Nakamura, Y. (1998) · PubMed · Cited by 514
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease
Eftekharzadeh, B., Daigle, J. G., Kapinos, L. E., Coyne, A., Schiantarelli, J., Carlomagno, Y., Cook, C., Miller, S. J., Dujardin, S., Amaral, A. S., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.07.039 · Cited by 460
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Doble, B. W., Patel, S., Wood, G. A., Kockeritz, L. K., & Woodgett, J. R. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.001 · Cited by 448
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
GSK-3 is a master regulator of neural progenitor homeostasis
Kim, W.-Y., Wang, X., Wu, Y., Doble, B. W., Patel, S., Woodgett, J. R., & Snider, W. D. (2009) · Nature Neuroscience · doi:10.1038/nn.2408 · Cited by 399
Phosphorylation of different tau sites during progression of Alzheimer’s disease
Neddens, J., Temmel, M., Flunkert, S., Kerschbaumer, B., Hoeller, C., Loeffler, T., Niederkofler, V., Daum, G., Attems, J., & Hutter-Paier, B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0557-6 · Cited by 384
The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329
Kurnit, K. C., Kim, G. N., Fellman, B. M., Urbauer, D. L., Mills, G. B., Zhang, W., & Broaddus, R. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.15 · Cited by 325
Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex
Dajani, R., Fraser, E., Roe, S. M., Yeo, M., Good, V. M., Thompson, V., Dale, T. C., & Pearl, L. H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg068 · Cited by 315
Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.
Eldar-Finkelman, H., Schreyer, S. A., Shinohara, M. M., LeBoeuf, R. C., & Krebs, E. G. (1999) · Diabetes · doi:10.2337/diabetes.48.8.1662 · Cited by 252
Tau phosphorylation affects its axonal transport and degradation
Rodríguez-Martín, T., Cuchillo-Ibáñez, I., Noble, W., Nyenya, F., Anderton, B. H., & Hanger, D. P. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.015 · Cited by 200
Boutajangout, A., Leroy, K., M., A., Anderton, B., Brion, J.-P., & Woodgett, J. (2002) · Acta Neuropathologica · doi:10.1007/s004010100435 · Cited by 186
Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes
Henriksen, E., & Dokken, B. (2006) · Current Drug Targets · doi:10.2174/1389450110607011435 · Cited by 185
Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy
Domoto, T., Pyko, I. V., Furuta, T., Miyashita, K., Uehara, M., Shimasaki, T., Nakada, M., & Minamoto, T. (2016) · Cancer Science · doi:10.1111/cas.13028 · Cited by 160
Yao, H.-B., Shaw, P., Wong, C.-C., & Wan, D. C. (2002) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(02)00014-5 · Cited by 152
GSK-3β and Microtubule Assembly in Axons
Zhou, F.-Q., & Snider, W. D. (2005) · Science · doi:10.1126/science.1110301 · Cited by 149
Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
[48] cDNA cloning and properties of glycogen synthase kinase-3
Robertwoodgett, J. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)00172-s · Cited by 144
Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain
Soutar, M. P. M., Kim, W.-Y., Williamson, R., Peggie, M. W., Hastie, C. J., McLauchlan, H., Snider, W. D., Gordon‐Weeks, P. R., & Sutherland, C. D. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06988.x · Cited by 139
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex
Carlyle, B. C., Nairn, A. C., Wang, M., Yang, Y., Jin, L. E., Simen, A. A., Ramos, B. P., Bordner, K. A., Craft, G. E., Davies, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322360111 · Cited by 139
Georgievska, B., Sandin, J., Doherty, J., Mörtberg, A., Neelissen, J. A. M., Andersson, A., Gruber, S. H. M., Nilsson, Y., Schött, P. A., Arvidsson, P. I., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12203 · Cited by 131
Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., MacDonald, C., Aboagye, A. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0889-12.2012 · Cited by 126 · cited 2×
“However, in a landmark study using a mouse model that combines amyloid and tau pathologies, Hurtado et al. (2012) reported that knockdown of either GSKα or β ameliorated tau hyperphosphorylation, yet only knockdown of GSK3α additionally reduced amyloid burden.”
BackgroundTau drives translational selectivity by interacting with ribosomal proteins
Koren, S. A., Hamm, M. J., Meier, S. E., Weiss, B. E., Nation, G. K., Chishti, E. A., Arango, J. P., Chen, J., Zhu, H., Blalock, E. M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01970-9 · Cited by 122
Functional Implications of Glycogen Synthase Kinase‐3‐Mediated Tau Phosphorylation
Hanger, D. P., & Noble, W. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/352805 · Cited by 118
Luna-Muñoz, J., García-Sierra, F., Falcón, V., Menéndez, I., Chávez-Macías, L., & Mena, R. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-8104 · Cited by 109
Developmental expression of p-glycoprotein (multidrug resistance gene product) in the rat brain
Matsuoka, Y., Okazaki, M., Kitamura, Y., & Taniguchi, T. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(19990605)39:3<383::aid-neu5>3.0.co;2-4 · Cited by 107
Banerji, V., Frumm, S. M., Ross, K. N., Li, L. S., Schinzel, A. C., Hahn, C. K., Kakoza, R. M., Chow, K. T., Ross, L., Alexe, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci46465 · Cited by 105
Wagner, F. F., Benajiba, L., Campbell, A. J., Weïwer, M., Sacher, J. R., Gale, J. P., Ross, L. S., Puissant, A., Alexe, G., Conway, A. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8460 · Cited by 105 · cited 2×
“…that exhibit paralog selectivity up to ∼7-fold.28 Additionally, a series of aminopyrazole inhibitors with up to 8- fold selectivity were reported by Wagner et al. (2018) and their development was based on the crystal structure of a GSK3β D133E mutant thought to mimic key differences between the…”
BackgroundPalomo, V., Pérez, D. I., Pérez, C., Morales-Garcia, J. A., Soteras, I., Alonso‐Gil, S., Encinas, A., Castro, A., Campillo, N. E., Pérez‐Castillo, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201463v · Cited by 95
GSK3 as a Sensor Determining Cell Fate in the Brain
Cole, A. R. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00004 · Cited by 88
Morgan-Smith, M., Wu, Y., Zhu, X., Pringle, J., & Snider, W. D. (2014) · eLife · doi:10.7554/elife.02663 · Cited by 76
GSK-3α/β kinases and amyloid production in vivo
Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., Borghgraef, P., Devijver, H., Kügler, S., Patel, S., et al. (2011) · Nature · doi:10.1038/nature10615 · Cited by 75
O’Leary, O. F., & Nolan, Y. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0213-z · Cited by 70
McCamphill, P. K., Stoppel, L. J., Senter, R. K., Lewis, M. C., Heynen, A. J., Stoppel, D. C., Sridhar, V., Collins, K. A., Shi, X., Pan, J. Q., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8572 · Cited by 64
Structure-based optimization of oxadiazole-based GSK-3 inhibitors
Monte, F. L., Kramer, T., Gu, J., Brodrecht, M., Pilakowski, J., Fuertes, A., Domínguez, J. M., Plotkin, B., Eldar-Finkelman, H., & Schmidt, B. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.06.006 · Cited by 53
Halkina, T., Henderson, J. L., Lin, E. Y.-S., Himmelbauer, M. K., Jones, J. H., Nevalainen, M., Feng, J., King, K. W., Rooney, M., Johnson, J. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00382 · Cited by 37
Self-citationReinecke, M., Heinzlmeir, S., Wilhelm, M., Médard, G., Klaeger, S., & Küster, B. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch4 · Cited by 29
Dillon, G. M., Henderson, J. L., Bao, C., Joyce, J. A., Calhoun, M. E., Amaral, B., King, K. W., Bajrami, B., & Rabah, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228771 · Cited by 29
Self-citationGSK3β, a Master Kinase in the Regulation of Adult Stem Cell Behavior
Racaud‐Sultan, C., & Vergnolle, N. (2021) · Cells · doi:10.3390/cells10020225 · Cited by 29
Wang, Y., Dou, X., Jiang, L., Jin, H., Zhang, L., Zhang, L., & Liu, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.039 · Cited by 27
Santos, J. R. F., Bauer, C., Schuchhardt, J., Wedekind, D., Waniek, K., Lachmann, I., Wiltfang, J., & Vogelgsang, J. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01982-5 · Cited by 26
Benítez, M. J., Cuadros, R., & Jiménez, J. S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201077 · Cited by 20
Stump, B., Shrestha, S., Lamattina, A. M., Louis, P. H., Cho, W., Perrella, M. A., Ai, X., Rosas, I. O., Wagner, F. F., Priolo, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213831 · Cited by 14
Research works printed but not linked: 1
- Miyoshi Y., 1998, Cancer Res., 58, 2524
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
GSK3: A potential target and pending issues for treatment of Alzheimer's disease
Zhao, J., Wei, M., Guo, M., Wang, M., Niu, H., Xu, T., & Zhou, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14818 · Cited by 295
Khan, Z. R., Welsby, P. J., Stasik, I., & Hayes, J. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00373 · Cited by 12
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 10
Valero-Rojas, J., Ramírez-Sánchez, C. A., Pacheco-Paternina, L., Valenzuela-Hormazábal, P., Saldívar‐González, F. I., Santana, P., González, J., Gutiérrez-Bunster, T., Valdés-Jiménez, A., & Ramírez, D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01481 · Cited by 8
Metadata
- Authors
- Amaral, B., Capacci, A., Anderson, T., Tezer, C., Bajrami, B., Lulla, M., Lucas, B., Chodaparambil, J. V., Marcotte, D., Kumar, P. R., Murugan, P., Spilker, K., Cullivan, M., Wang, T., Peterson, A. C., Enyedy, I., Ma, B., Chen, T., Yousaf, Z., Calhoun, M., Golonzhka, O., Dillon, G. M., & Koirala, S.
- Affiliations
- Biogen (United States) (US)
- Corresponding author
- Capacci, Andrew
- ORCID
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-02-22
- Volume
- 14
- Issue
- 6
- Pages
- 1080-1094
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC10020971
- OpenAlex
- W4321488198
- Cited by
- 22
- References
- 59
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 5
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- glycogen synthase kinase-3, GSK3α, GSK3β, crystal structure, kinase inhibitor design, Wnt/β-catenin signaling, tau phosphorylation, chemoproteomics, Alzheimer's disease, kinase selectivity
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Phosphorylation, Protein Serine-Threonine Kinases, Glycogen Synthase Kinase 3, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.